By Habib Ur Rehman
Publication Date: 2026-09-23 18:42:00
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to design small-molecule programs across immunology, neuroscience and oncology. The public-stock question is not whether Iambic becomes the next Nvidia. It is whether AI models can shorten an expensive part of pharma R&D enough to create measurable value for the chip supplier and the drug company at opposite ends of the workflow.
To see why faster discovery is only the first filter, we recently examined how AtaiBeckley is building its valuation case around Phase 3 readiness, and how Merck is using KEYTRUDA and WELIREG to deepen a cancer franchise. Iambic’s IPO sits much earlier in that value chain, which is precisely why investors should ask who benefits if its molecules advance—and who still carries the clinical risk.
AbbVie gets optionality without buying the platform
AbbVie Inc. (NYSE:ABBV) can use Iambic’s Enchant platform to search chemical space and optimize molecules while keeping its own clinical-development and commercialization machinery. The agreement includes a $40 million upfront payment, up to $670 million in development and sales-based milestones across the…
